Table Of Contents:
- Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
- Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
- Chapter 3. Diabetic Kidney Disease (DKD) Market: By Product Type
- Angiotensin-Converting Enzyme (ACE) Inhibitors Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Angiotensin-Converting Enzyme (ACE) Inhibitors Definitions, Technology Landscape
- Angiotensin-Converting Enzyme (ACE) Inhibitors Market Drivers
- Product Launches
- Technology Launches
- Angiotensin-Converting Enzyme (ACE) Inhibitors Market Restraints
- Chapter 4. Diabetic Kidney Disease (DKD) Market: By Disease Stage
- Early-Stage DKD Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Early-Stage DKD Definitions, Technology Landscape
- Early-Stage DKD Market Drivers
- Product Launches
- Technology Launches
- Early-Stage DKD Market Restraints
- Chapter 5. Diabetic Kidney Disease (DKD) Market: By Route of Administration
- Oral Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Oral Definitions, Technology Landscape
- Oral Market Drivers
- Product Launches
- Technology Launches
- Oral Market Restraints
- Chapter 6. Diabetic Kidney Disease (DKD) Market: By Distribution Channel
- Hospitals Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Hospitals Definitions, Technology Landscape
- Hospitals Market Drivers
- Product Launches
- Technology Launches
- Hospitals Market Restraints
- Chapter 7. Diabetic Kidney Disease (DKD) Market: By End User
- Hospitals Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Hospitals Definitions, Technology Landscape
- Hospitals Market Drivers
- Product Launches
- Technology Launches
- Hospitals Market Restraints
- Chapter 8. Diabetic Kidney Disease (DKD) Market: Regional Market Trends, Size, and Future Outlook
- North America
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Europe
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Latin America
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- North America
- Chapter 9. Diabetic Kidney Disease (DKD) Market: Competitive Landscape
- Novo Nordisk A/S
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bayer AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- AstraZeneca plc
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Eli Lilly and Company
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Merck & Co., Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Sanofi S.A.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Johnson & Johnson
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Mitsubishi Tanabe Pharma Corporation
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Daiichi Sankyo Company, Limited
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Abbvie Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Otsuka Holdings Co., Ltd.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Gilead Sciences, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novo Nordisk A/S
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Diabetic Kidney Disease (DKD) industry is USD 7,210 million.
The rising prevalence of diabetes, increasing awareness of DKD, advancements in diagnostics, and the growing demand for effective treatments are the key factors contributing significantly to the growth of the Diabetic Kidney Disease (DKD) market.
The key factors hampering the growth of the Diabetic Kidney Disease (DKD) Market include the side effects of DKD medications, high cost of treatments, limited access to healthcare in some regions, and lack of awareness about DKD in certain populations.
The leading component segment in the Diabetic Kidney Disease (DKD) Market is the SGLT2 Inhibitors, which have shown promising results in delaying the progression of DKD.
The major players operating in the Diabetic Kidney Disease (DKD) Market include Novo Nordisk A/S, Bayer AG, AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Company, Limited.
The Diabetic Kidney Disease (DKD) Market is expected to grow at a CAGR of 7.8% from 2023 to 2031, with a market size of USD 13,148.8 million by 2031.
The key drivers of the Diabetic Kidney Disease (DKD) Market include the rising prevalence of diabetes, increasing awareness of DKD, advancements in diagnostic tools, growing demand for effective treatments, and the focus on early intervention.